ITeos Therapeutics Inc
ITOS
Market Cap$365.95M
Close$
$2.28
66% downside
Current Fair Value
66% downsideOvervalued by 66% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $365.95 Million |
|---|---|
| Enterprise Value | $214.19 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.15 |
| Beta | 1.36 |
| Outstanding Shares | 39,699,053 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.68 |
|---|---|
| PEG | -9.04 |
| Price to Sales | - |
| Price to Book Ratio | 0.48 |
| Enterprise Value to Revenue | 9.04 |
| Enterprise Value to EBIT | -1.45 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About ITeos Therapeutics Inc
62 employeesiTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep under...